Medicines

Here you will find the recommendations we have made about the use of individual medicines in Lancashire.

Ertugliflozin with metformin and a dipeptidyl peptidase‑4 inhibitor

Brand: 
NICE TA: 583
Indication: Treating type 2 diabetes (NICE TA583)
Disease category: Endocrine system
Commissioning responsibility: CCG
PbR excluded: No

Background

1.1 Ertugliflozin with metformin and a dipeptidyl peptidase‑4 (DPP‑4) inhibitor is recommended as an option for treating type 2 diabetes in adults when diet and exercise alone do not provide adequate glycaemic control, only if: the disease is uncontrolled with metformin and a DPP‑4 inhibitor, and a sulfonylurea or pioglitazone is not appropriate.

Recommendation

LMMG recommendation: Green (Restricted)
Click here to find the definitions for the colour classifications

Reason for decision:  Suitable for initiation in primary care provided the additional criteria specific to the medicine or device are met

Supporting documents:

NICE TA583 - Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes

Decisions of Lancashire local decision making groups:

NHS Blackburn With Darwen CCG and NHS East Lancashire CCG NHS Blackpool CCG NHS Chorley and South Ribble CCG and NHS Greater Preston CCG NHS Fylde and Wyre CCG NHS Morecambe Bay CCG NHS West Lancashire CCG

Green

Green (Restricted)

Green (Restricted)

Green (restricted)

Green (Restricted)

Green (Restricted)